Female neuregulin 1 heterozygous mice require repeated exposure to Δ9-tetrahydrocannabinol to alter sensorimotor gating function

Pharmacopsychiatry

Volumn 46, Issue 7, 2013, Pages 286-291

  Spencer, J R ^a   Chohan, T W ^a   Karl, T ^b,c,d   Arnold, J C ^a,c  

^a UNIVERSITY OF SYDNEY   (Australia)

^b NEUROSCIENCE RESEARCH AUSTRALIA   (Australia)

^c Schizophrenia Research Institute   (Australia)

^d UNIVERSITY OF NEW SOUTH WALES   (Australia)

Author keywords

animal model; cannabis; neuregulin 1; prepulse inhibition; schizophrenia

Indexed keywords

DRONABINOL; NEU DIFFERENTIATION FACTOR;

ACUTE DRUG ADMINISTRATION; ANIMAL EXPERIMENT; ANIMAL MODEL; ANXIETY; ARTICLE; CONTROLLED STUDY; DRUG EXPOSURE; DRUG TOLERANCE; FACILITATION; FEMALE; GENOTYPE; HETEROZYGOTE; LIGHT DARK CYCLE; LOCOMOTION; MOUSE; NEUROTOXICITY; NONHUMAN; OUTCOME ASSESSMENT; PREPULSE INHIBITION; PRIORITY JOURNAL; RAT; REPEAT PROCEDURE; SENSORIMOTOR FUNCTION; SENSORY DYSFUNCTION; SENSORY GATING; STARTLE REFLEX;

ANIMALS; ANXIETY; DRONABINOL; FEMALE; GENOTYPE; HETEROZYGOTE; MICE; NEUREGULIN-1; SENSORY GATING;

EID: 84887837614     PISSN: 01763679     EISSN: 14390795     Source Type: Journal    
DOI: 10.1055/s-0033-1355390     Document Type: Article

References (44)

1. Sullivan P. F., Kendler K. S., Neale M. C. Schizophrenia as a complex trait: evidence from a meta-analysis of twin studies. Arch Gen Psychiatry: 2003; 60 1187 1192 (Pubitemid 37494071)
2. Myles N., Newall H., Nielssen O. et al. The association between cannabis use and earlier age at onset of schizophrenia and other psychoses: meta-analysis of possible confounding factors. Curr Pharm Des: 2012; 18 5055 5069
3. Arnold J. C., Boucher A. A., Karl T. The yin and yang of cannabis-induced psychosis: the actions of delta(9)-tetrahydrocannabinol and cannabidiol in rodent models of schizophrenia. Curr Pharm Des: 2012; 18 5113 5130
4. Pelayo-Teran J. M., Suarez-Pinilla P., Chadi N. et al. Gene-environment interactions underlying the effect of cannabis in first episode psychosis. Curr Pharm Des: 2012; 18 5024 5035
5. Stefansson H., Sigurdsson E., Steinthorsdottir V. et al. Neuregulin 1 and susceptibility to schizophrenia. Am J Hum Genet: 2002; 71 877 892 (Pubitemid 135750519)
6. Munafo M. R., Thiselton D. L., Clark T. G. et al. Association of the NRG1 gene and schizophrenia: a meta-analysis. Mol Psychiatry: 2006; 11 539 546
7. Munafo M. R., Attwood A. S., Flint J. Neuregulin 1 genotype and schizophrenia. Schizophr Bull: 2008; 34 9 12 (Pubitemid 350262294)
8. Mei L., Xiong W. C. Neuregulin 1 in neural development, synaptic plasticity and schizophrenia. Nat Rev Neurosci: 2008; 9 437 452 (Pubitemid 351704944)
9. Chong V. Z., Thompson M., Beltaifa S. et al. Elevated neuregulin-1 and ErbB4 protein in the prefrontal cortex of schizophrenic patients. Schizophr Res: 2008; 100 270 280
10. Marballi K., Cruz D., Thompson P. et al. Differential neuregulin 1 cleavage in the prefrontal cortex and hippocampus in schizophrenia and bipolar disorder: preliminary findings. PLoS One: 2012; 7 e36431
11. Hall J., Whalley H. C., Job D. E. et al. A neuregulin 1 variant associated with abnormal cortical function and psychotic symptoms. Nat Neurosci: 2006; 9 1477 1478 (Pubitemid 44862654)
12. Keri S., Kiss I., Kelemen O. Effects of a neuregulin 1 variant on conversion to schizophrenia and schizophreniform disorder in people at high risk for psychosis. Mol Psychiatry: 2009; 14 118 119
13. Bousman C. A., Yung A. R., Pantelis C. et al. Effects of NRG1 and DAOA genetic variation on transition to psychosis in individuals at ultra-high risk for psychosis. Transl Psychiatry: 2013; 3 e251
14. Karl T., Duffy L., Scimone A. et al. Altered motor activity, exploration and anxiety in heterozygous neuregulin 1 mutant mice: implications for understanding schizophrenia. Genes Brain Behav: 2007; 6 677 687 (Pubitemid 47476190)
15. O'Tuathaigh C. M., Harte M., O'Leary C. et al. Schizophrenia-related endophenotypes in heterozygous neuregulin-1 'knockout' mice. Eur J Neurosci: 2010; 31 349 358
16. O'Tuathaigh C. M., O'Connor A. M., O'Sullivan G. J. et al. Disruption to social dyadic interactions but not emotional/anxiety-related behaviour in mice with heterozygous 'knockout' of the schizophrenia risk gene neuregulin-1. Prog Neuropsychopharmacol Biol Psychiatry: 2008; 32 462 466 (Pubitemid 351178964)
17. Spencer J. R., Darbyshire K. M., Boucher A. A. et al. Adolescent neuregulin 1 heterozygous mice display enhanced behavioural sensitivity to methamphetamine. Prog Neuropsychopharmacol Biol Psychiatry: 2012; 39 376 381
18. Roussos P., Giakoumaki S. G., Adamaki E. et al. The influence of schizophrenia-related neuregulin-1 polymorphisms on sensorimotor gating in healthy males. Biol Psychiatry: 2011; 69 479 486
19. Cadenhead K. S. Startle reactivity and prepulse inhibition in prodromal and early psychosis: effects of age, antipsychotics, tobacco and cannabis in a vulnerable population. Psychiatry Res: 2011; 188 208 216
20. Aleman A., Kahn R. S., Selten J. P. Sex differences in the risk of schizophrenia: evidence from meta-analysis. Arch Gen Psychiatry: 2003; 60 565 571 (Pubitemid 36682313)
21. Leung A., Chue P. Sex differences in schizophrenia, a review of the literature. Acta Psychiatr Scand Suppl: 2000; 401 3 38 (Pubitemid 30412890)
22. Han S., Yang B. Z., Kranzler H. R. et al. Linkage analysis followed by association show NRG1 associated with cannabis dependence in African Americans. Biol Psychiatry: 2012; 72 637 644
23. Tabares-Seisdedos R., Rubenstein J. L. Chromosome 8p as a potential hub for developmental neuropsychiatric disorders: implications for schizophrenia, autism and cancer. Mol Psychiatry: 2009; 14 563 589
24. Long L. E., Chesworth R., Arnold J. C. et al. A follow-up study: acute behavioural effects of delta(9)-THC in female heterozygous neuregulin 1 transmembrane domain mutant mice. Psychopharmacology (Berl): 2010; 211 277 289
25. Long L. E., Chesworth R., Huang X. F. et al. Transmembrane domain Nrg1 mutant mice show altered susceptibility to the neurobehavioural actions of repeated THC exposure in adolescence. Int J Neuropsychopharmacol: 2013; 16 163 175
26. Nakamura E. M., da Silva E. A., Concilio G. V. et al. Reversible effects of acute and long-term administration of delta-9-tetrahydrocannabinol (THC) on memory in the rat. Drug Alcohol Depend: 1991; 28 167 175
27. Stiglick A., Kalant H. Residual effects of prolonged cannabis administration on exploration and DRL performance in rats. Psychopharmacology (Berl): 1982; 77 124 128 (Pubitemid 12100085)
28. Quinn H. R., Matsumoto I., Callaghan P. D. et al. Adolescent rats find repeated delta(9)-THC less aversive than adult rats but display greater residual cognitive deficits and changes in hippocampal protein expression following exposure. Neuropsychopharmacology: 2008; 33 1113 1126 (Pubitemid 351367534)
29. Boucher A. A., Hunt G. E., Micheau J. et al. The schizophrenia susceptibility gene neuregulin 1 modulates tolerance to the effects of cannabinoids. Int J Neuropsychopharmacol: 2011; 14 631 643
30. van den Buuse M., Wischhof L., Lee R. X. et al. Neuregulin 1 hypomorphic mutant mice: enhanced baseline locomotor activity but normal psychotropic drug-induced hyperlocomotion and prepulse inhibition regulation. Int J Neuropsychopharmacol: 2009; 12 1383 1393
31. Boucher A. A., Arnold J. C., Duffy L. et al. Heterozygous neuregulin 1 mice are more sensitive to the behavioural effects of delta9- tetrahydrocannabinol. Psychopharmacology (Berl): 2007; 192 325 336 (Pubitemid 46705399)
32. Tsou K., Patrick S. L., Walker J. M. Physical withdrawal in rats tolerant to delta 9-tetrahydrocannabinol precipitated by a cannabinoid receptor antagonist. Eur J Pharmacol: 1995; 280 R13 R15
33. Newell K. A., Karl T., Huang X. F. A neuregulin 1 transmembrane domain mutation causes imbalanced glutamatergic and dopaminergic receptor expression in mice. Neuroscience: 2013; 17 670 680
34. Derkinderen P., Ledent C., Parmentier M. et al. Cannabinoids activate p38 mitogen-activated protein kinases through CB1 receptors in hippocampus. J Neurochem: 2001; 77 957 960 (Pubitemid 32466793)
35. Eto K., Hommyo A., Yonemitsu R. et al. ErbB4 signals neuregulin1- stimulated cell proliferation and c-fos gene expression through phosphorylation of serum response factor by mitogen-activated protein kinase cascade. Mol Cell Biochem: 2010; 339 119 125
36. Iwakura Y., Nawa H. ErbB1-4-dependent EGF/neuregulin signals and their cross talk in the central nervous system: pathological implications in schizophrenia and Parkinson's disease. Front Cell Neurosci: 2013; 7 4
37. Kellert B. A., Nguyen M. C., Nguyen C. et al. Estrogen rapidly attenuates cannabinoid-induced changes in energy homeostasis. Eur J Pharmacol: 2009; 622 15 24
38. Glanowska K. M., Moenter S. M. Endocannabinoids and prostaglandins both contribute to GnRH neuron-GABAergic afferent local feedback circuits. J Neurophysiol: 2011; 106 3073 3081
39. Huang G. Z., Woolley C. S. Estradiol acutely suppresses inhibition in the hippocampus through a sex-specific endocannabinoid and mGluR-dependent mechanism. Neuron: 2012; 74 801 808
40. Begemann M. J., Dekker C. F., van Lunenburg M. et al. Estrogen augmentation in schizophrenia: a quantitative review of current evidence. Schizophr Res: 2012; 141 179 184
41. Ghafari E., Fararouie M., Shirazi H. G. et al. Combination of estrogen and antipsychotics in the treatment of women with chronic schizophrenia: a double-blind, randomized, placebo-controlled clinical trial. Clin Schizophr Relat Psychoses: 2013; 6 172 176
42. Gogos A., Kwek P., van den Buuse M. The role of estrogen and testosterone in female rats in behavioral models of relevance to schizophrenia. Psychopharmacology (Berl): 2012; 219 213 224
43. Gogos A., Kwek P., Chavez C. et al. Estrogen treatment blocks 8-hydroxy-2-dipropylaminotetralin- and apomorphine-induced disruptions of prepulse inhibition: involvement of dopamine D1 or D2 or serotonin 5-HT1A, 5-HT2A, or 5-HT7 receptors. J Pharmacol Exp Ther: 2010; 333 218 227
44. Takeda S., Yoshida K., Nishimura H. et al. Delta-tetrahydrocannabinol disrupts estrogen-signaling through up-regulation of estrogen receptor b (ERb). Chem Res Toxicol: 2013; 10.1021/tx4000446